畲药益肾泻浊方治疗早中期慢性肾衰竭的临床效果观察  

Clinical effect of she medicine Yishen Xiezhuo decoction in the treatment of early and middle stage chronic renal failure

作　　者：刘小菊[1] 王慧 黄德慧[1] 余军[1] 卓和伟 雷后兴[1] LIU Xiao-ju;WANG Hui;HUANG De-hui;YU Jun;ZHUHe-wei;LEI Hou-xing(Lishui Hospital of traditional Chinese medicine,Lishui Hospital of traditional Chinese Medicine Affiliated to Zhejiang University of traditional Chinese Medicine Lishui,Zhejiang 323000)

机构地区：[1]浙江丽水市中医院浙江中医药大学附属丽水中医院,浙江丽水323000

出　　处：《中国民族医药杂志》2021年第8期1-5,共5页Journal of Medicine and Pharmacy of Chinese Minorities

基　　金：浙江省中医药科技项目(2019ZA131);2019年浙江省科技厅公益项目资助(LGF20H280005);2020年浙江省中管局适宜技术项目(2020ZT013)。

摘　　要：目的:探究畲药益肾泻浊方治疗早中期慢性肾衰竭的临床效果。方法:选择我院2019年7月—2020年12月收治的80例确诊为早中期慢性肾衰竭(CKD2-3期)的患者作为研究对象,采用前瞻性研究方法,按照治疗方式不同将患者分为对照组(40例),采用常规疗法;观察组(40例),在常规疗法基础上加用畲药益肾泻浊方治疗。比较两组治疗前后中医证候积分、肾功能指标(内生肌酐清除率(Ccr)、血肌酐(Scr)、血尿素氮(BUN))、炎症因子指标(肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、C反应蛋白(CRP)),治疗末期患者终末期肾衰竭(ESRD)发生率、不良反应发生情况。结果:两组治疗后比较:观察组中医证候积分明显下降,低于对照组;观察组Ccr明显高于对照组,Scr、BUN明显低于对照组;观察组TNF-α、IL-6、CRP数据均明显低于对照组,各项指标统计学分析,差异均有统计学意义(P<0.05)。观察组治疗末期未发生ESRD,对照组发生3例(7.50%,3/40),差异无统计学意义(P>0.05)。治疗期间均未发生严重不良反应。结论:畲药益肾泻浊方治疗早中期慢性肾衰竭,可有效改善患者机体炎症反应及临床症状,提升肾功能,延缓慢性肾衰竭进展,安全性高,值得临床应用与推广。Objective:The objective of the study is to explore the clinical therapeutic effect of She medicine Yishe Xiezhuo decoction, a traditional medicine of invigorating kidney and purgation, in the treatment of chronic kidney failure at early and middle stage. Methods: 80 patients confirmed as chronic renal failure at early and middle stage in our hospital from July 2019 to December 2020 were selected as the subjects of the study. The prospective study method was adopted. According to different treatment methods, the patients were divided into control group(40 cases),which were treated with conventional therapy, and observation group(40 cases), which were treated with She medicine Yishe Xiezhuo decoction on the basis of conventional therapy. The patients in the two groups were compared before and after treatment in TCM syndrome scores, renal function index(endogenous creatinine clearance rate(Ccr), serum creatinine(Scr)and blood urea nitrogen(BUN)), inflammatory factor index(tumor necrosis factor alpha(TNF-α), interleukin 6(IL-6) and c-reactive protein(CRP)). The incidence of end-stage renal failure(ESRD) and adverse reactions in patients at the end of treatment were also compared. Results: The comparison between patients in the two groups after the treatment: TCM syndrome score of the observation group decreased significantly, lower than that of the control group;CCR of the observation group was significantly higher than that of the control group, SCR and BUN were significantly lower than that of the control group;The TNF-α, IL-6 and CRP data of the observation group were significantly lower than those of the control group, and the statistical analysis of various indicators showed that the differences in the data were statistically significant(P <0.05);ESRD patients of the observation group did not occur at the end of treatment, while 3 cases(7.50%,3/40) in the control group did occur, but the data difference was not statistically significant(P>0.05). No serious adverse reactions occurred during treatment in the two

关 键 词：畲药 益肾泻浊 慢性肾衰竭 炎性因子 肾功能 不良反应 

分 类 号：R298.3[医药卫生—民族医学]